Early antiretroviral therapy mortality in resource-limited settings: What can we do about it?

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 346-351

  Bekker, Linda Gail ^a,b   Egger, Matthias ^c   Wood, Robin ^a  

^a Institute of Infectious Disease and Molecular Medicine   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Early mortality; Resource limited ART programs

Indexed keywords

NEVIRAPINE; STAVUDINE;

CD4 LYMPHOCYTE COUNT; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; LACTIC ACIDOSIS; MORTALITY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME;

EID: 34250667362     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3281e72cbd     Document Type: Review

References (76)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
3. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423. [Erratum, Arch Intern Med 2005; 165:1200]
4. Walensky RP, Paltiel AD, Losina E, et al. AIDS drugs have saved 3 million years of life in the USA. J Infect Dis 2006; 194:11-19. This study highlights the very significant advances made in AIDS care between 1989 and 2003 in the USA.
5. WHO/UNAIDS. Progress of global access to HIV antiretroviral therapy: an update on '3 by 5' June 2005. http://www.who.int/hiv/pub/progressreports/ 3by5%20Progress%20Report_E_light.pdf. [Accessed 27 March 2007]
6. WHO/UNAIDS. Press release: HIV infection rates decreasing in several countries but global number of people living with HIV continues to rise. November, 2005. http://www.who.int/hiv/epiupdate2005/en/print.html. [Accessed 27 March 2007]
7. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2006. Geneva: WHO.
8. United Nations General Assembly Special Session on HIV/AIDS 2006. Stop AIDS: keep the promise. http//www.ungass.org/. [Accessed 30 March 2007]
9. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary healthcare sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
10. Harries AD, Schouten EJ, Limbamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367:1870-1872.
11. Braitstein P, Brinkhof MW, Dabis F, et al., Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1 patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824. The first comparative study of virologic and clinical outcomes of large cohorts receiving ART in the southern hemisphere and Europe and North America.
12. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
13. Lawn SD, Myer L, Bekker L-G, Wood R. Early mortality among adults accessing a community based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
14. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. An important study which documents significant non-AIDS related disease at higher CD4 cell counts in those temporarily discontinuing ART.
15. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death among HIV-1 infected individuals prior to widespread availability of antiretroviral therapy in South Africa. Lancet 2006; 368:1254-1259. An important cohort study documenting high morbidity and mortality in patients with moderate immune deficiency in South Africa.
16. Post FA, Badri M, Wood R, Maartens G. AIDS in Africa: survival according to AIDS-defining illness. S Afr Med J 2001; 91:583-586.
17. Morgan D, Malamba SS, Orem J, et al. Survival by AIDS defining condition in rural Uganda. Sex Transm Infect 2000; 76:193-197.
18. Ghirardini A, Puopolo M, Rossetti G, et al., The Italian Group on Congenital Coagulopathies. Survival after AIDS among Italian haemophiliacs with HIV infection. AIDS 1995; 9:1351-1356.
19. Whitmore-Overton SE, Tillett HE, Evans BG, Allardice GM. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993; 7:415-420.
20. Del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12:1203-1209.
21. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003. http://www.who.int/hiv/ pub/prev_care/en/arvrevision2003en.pdf. [Accessed 27 March 2007]
22. Egger M. Outcomes of ART in resource limited and industrialized countries. Oral abstract 22. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, USA.
23. UNAIDS. Rural vs urban HIV. http://unaids.org/topics/gender/ruralHIVAIDS- en.pdf. [Accessed 9 April 2007]
24. CDC. Cases of HIV infection and AIDS in the United States 2004. HIV/AIDS Surveillance Report 2005; 16:16-45.
25. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behaviour in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39:446-453.
26. UNAIDS. Fact sheet: sub-Saharan Africa. http://www.who.int/hiv/ mediacentre/200605-FS_SubSaharanAfrica_en.pdf.
27. Roth DL, Stewart KE, Clay OJ, et al. Sexual practices of HIV discordant and concordant couples in Rwanda: effects of a testing and counselling programme for men. Int J STD AIDS 2001; 12:181-188.
28. UNAIDS. AIDS Epidemic Update: 2006 Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). 2006. Geneva.
29. IAS-USA Guidelines 2004. When to start ART. JAMA 2004; 292:251.
30. British HIV Association. When to start treatment: draft guidelines. 2005. http://bhiva.org/guidelines/2005/BHIVAguidelines/index.html. [Accessed 11 March 2007]
31. Rabkin M, El-Sadr W, Katzenstein DA, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002; 360:1503-1505.
32. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
33. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
34. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
35. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
36. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins sans Frontières. AIDS 2003; 17:1995-1997.
37. Lawn SD, Myer L, Wood R. Efficacy of antiretroviral therapy in resource-poor settings: are outcomes comparable to those in the developed world? Clin Infect Dis 2005; 41:1683-1684.
38. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38:174-179.
39. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Inf Dis 2006; 43:770-776. A study to raising awareness of pre-ART and early ART mortality.
40. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
41. Orrell C, Harling G, Lawn SD, et al. Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy 2007; 12:83-88.
42. Badri M, Cleary S, Maartens G, et al. When to initiate HAART in sub-Saharan Africa: a cost-effectiveness study. Antiviral Therapy 2006; 11:63-72.
43. Anglaret X, Messou E, Ouassa T, et al. Patterns of bacterial diseases in a cohort of HIV-infected adults receiving cotrimoxazole prophylaxis in Abijan, Cote d'Ivoire. AIDS 2003; 17:575-584.
44. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Uganda: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16:597-603.
45. Colebunders R, Ryder R, Francis H, et al. Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. J Infect Dis 1991; 3:450-456.
46. Lindan CP, Allen S, Serulira A, et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 1992; 4:320-328.
47. Whittle H, Egboga A, Todd J, et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992; 7:685-689.
48. Malamba SS, Morgan D, Clayton T, et al. The prognostic value of the World Health Organisation staging system for HIV infection and disease in rural Uganda. AIDS 1999; 18:2555-2562.
49. Scott JA, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355:1225-1230.
50. Post FA, Badri M, Wood R, Maartens G. AIDS in Africa: survival according to AIDS-defining illness. S Afr Med J 2001; 7:583-586.
51. Alabi AS, Jaar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 10:1513-1520.
52. Wolff B, Nyanzi B, Katangole G, et al. Evaluation of a home based voluntary counseling and testing intervention in rural Uganda. Health Policy Plan 2005; 20:109-116.
53. CDC. Introduction of routine HIV testing in prenatal care: Botswana, 2004. MMWR 2004; 53:1083-1086.
54. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. MMWR 1992; 41:1-19.
55. Badri M, Bekker LG, Orrell C, et al. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling up guidelines. AIDS 2004; 18:1159-1168.
56. Anglaret X, Chene G, Attia A, et al., Cotrimo-Cl Study Group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1 infected adults in Abijan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1463-1468.
57. Tiamson ML. Challenges in the management of the HIV patient in the third decade of AIDS. Psychiatr Q 2002; 73:51-58.
58. Wilson DP, Blower S. Allocating antiretrovirals in South Africa: Using modeling to determine treatment equity. PLoS Med 2005; 2:e155.
59. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18 (Suppl 3):S21-S25.
60. Bekker LG, Orrell C, Reader L, et al. Antiretroviral therapy in a community clinic: early lessons from a pilot project. S Afr Med J 2003; 93:458-462.
61. South Africa National Department of Health. National Antiretroviral Treatment Guidelines. 2004. Pretoria: South African Ministry of Health.
62. Harries AD, Nyangulu DS, Hargreaves NJ, et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-414.
63. Orrell C, Harling G, Lawn S, et al. Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy 2006 (in press).
64. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2005; 2:171-176.
65. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006; 96:315-320.
66. Coetzee D, Boulle A, Hildebrand K, et al. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 2004; 18 (Suppl 3):S27-S31.
67. Badri M, Mandalia S, Martens G, et al. Impact of highly active antiretroviral therapy on use cost and outcome of HIV healthcare provision in Cape Town, South Africa: 1995-2000. PLoS Med 2005; 3:e4.
68. Wood R. Nevirapine toxicity and implications for the South African ARV-rollout program [review]. S Afr Med J 2005; 95:253-257.
69. Boulle A, Orrell C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first three years of ART in a large South African cohort. 2007 (in press).
70. Wood R. The role of stavudine in the South African public sector antiretroviral program: should the perfect be the enemy of the good. S African Journal of HIV Medicine 2006; 23:5-8.
71. Lawn SD, Myer L, Bekker L-G, Wood R. Burden of tuberculosis in a South African antiretroviral treatment (ART) service: impact on ART outcomes and implications for TB control. AIDS 2006; 20:1605-1612.
72. Lucas SB, de Cock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. Br Med J 1994; 308:1531-1533.
73. Lawn S, Myer l, Bekker L-G, Wood R. Early mortality among patients with HIV-associated TB in Africa: implications for the time to initiate ART. Abstract 81. 14th Conference on Retroviruses and Opportunistic infections; 25-28 February; Los Angeles, CA, USA.
74. Lawn SD, Wood R. How can earlier entry of patients into antiretroviral programmes in low-income countries be promoted? Clin Infect Dis 2006; 42:431-432.
75. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
76. Lawn SD, Bekker L-G, Myer L, et al. Cryptoccocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 9:2050-2052.